Page 4 - FIMM_Brochure_2022
P. 4
iFnIMa NMuRtsehseelal rch
FIGKUERYES At FIMM, we strive for people-centred research with direct
translational impact on the Finnish population. At the same
Number of Grand Challenge time, we aim to maintain a profile of scientific excellence at the
highest level, globally, as measured by traditional metrics of
4Programmes publications and international projects.
22Number of research groups Within translational molecular medicine, FIMM pursues ‘Grand Challenge’ research in
four areas: the development of individualised cancer medicine (1), novel diagnostics
20Number of active EU projects via imaging of tissues and cells (2) and the use of genomics (3) and epidemiology (4)
to better understand and predict disease. The major diseases of interest are cancer,
cardiovascular, neuropsychiatric and immune-mediated diseases.
Much of our research draws on unique biobank samples collected from the Finnish
founder population and on the close partnerships we have with clinical and indus-
trial collaborators. Through our science, we are uncovering the underlying causes
and drivers of disease and are translating medically relevant molecular findings into
population and individual health outcomes.
FIMM research is primarily organised into four Grand Challenge programmes
(p. 6-13), each led by a research director, providing an opportunity to align our
research on large and complex issues. In these projects, researchers, technology
experts and clinical collaborators from different FIMM research groups, Technology
Centre units and other organisations, respectively, are drawn together to achieve
common goals through interdisciplinary collaboration.
As of August 2022, FIMM has 22 research groups (p. 16–17). EMBL-style group leader
positions (generally 5 years in length, with potential for a 4-year renewal) are at the
heart of the institute, alongside the research directors who also lead research groups
within their Grand Challenge areas.
FIMM maintains a wealth of global partnerships with academic and industry groups.
We are in close collaborative relationships with research institutions around the
globe, strengthened by shared appointments of several of our directors and group
leaders at other top institutions, including SciLifeLab, Karolinska Institutet, and the
Broad Institute of MIT and Harvard. More than half of our doctoral students and
postdoctoral researchers are from abroad, making FIMM a truly global community.
|4 FIMM – Building a Bridge from Discovery to Medicine
